Q-omics provides the consensus-scored NPBWR1 profile across patient tissues and cancer cell-line models. NPBWR1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, NPBWR1 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, NPBWR1 RNA expression shows 13,633 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, HNSC, and TGCT as cancer lineages where NPBWR1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NPBWR1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NPBWR1 survival associations across molecular data types. NPBWR1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NPBWR1 RNA expression–survival associations across cancer types. High NPBWR1 expression shows unfavorable associations in UVM, UCEC, KIRP, BRCA, LUAD and KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for NPBWR1 RNA expression.
This table summarizes NPBWR1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for NPBWR1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NPBWR1 shows higher tumor expression in HNSC, LUAD, KIRP, BLCA, LUSC and COAD. The HNSC box plot shows higher NPBWR1 RNA expression in tumor versus normal tissue (log2 FC = +2.012, t-test p < 0.001).
This table shows molecular features associated with NPBWR1 in patient tissues and cancer cell lines. In patient samples, NPBWR1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, NPBWR1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
